HIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction for PWID includes needle-syringe programs (NSPs) and opioid substitution therapy (OST) but often coupled with antiretroviral therapy (ART) for people living with HIV. Numerous studies have examined the effectiveness of each harm reduction strategy. This commentary discusses the evidence of effectiveness of the packages of harm reduction services and their cost-effectiveness with respect to HIV-related outcomes as well as estimate resources required to meet global and regional coverage targets. NSPs have been shown to be safe and very effective in reducing HIV transmission in diverse settings; there are many historical and very recent examples in dive...
Aims: To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting...
To end the AIDS epidemic by 2030, the global response to HIV must leave no one behind, including peo...
Abstract: Policy discussions about the feasibility of massively scaling up antiretroviral therapy (A...
AbstractHIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction ...
HIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction for PWID...
AIMS:Two behavioral HIV prevention interventions for people who inject drugs (PWID) infected with HI...
Two behavioral HIV prevention interventions for people who inject drugs (PWID) infected with HIV inc...
BACKGROUND:The risks of HIV transmission associated with the opioid epidemic make cost-effective pro...
Background Harm reduction strategies commonly include needle and syringe programmes (NSP), opioid su...
BACKGROUND: Pre-exposure prophylaxis with oral antiretroviral treatment (oral PrEP) for HIV-uninfect...
Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HI...
Pre-exposure prophylaxis with oral antiretroviral treatment (oral PrEP) for HIV-uninfected injection...
OBJECTIVES: The objectives of this study were to estimate the cost-effectiveness of a harm reduction...
BackgroundPersons who inject drugs (PWID) are at a disproportionately high risk of HIV infection. We...
HIV can spread rapidly between people who inject drugs (through injections and sexual transmission),...
Aims: To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting...
To end the AIDS epidemic by 2030, the global response to HIV must leave no one behind, including peo...
Abstract: Policy discussions about the feasibility of massively scaling up antiretroviral therapy (A...
AbstractHIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction ...
HIV prevalence worldwide among people who inject drugs (PWID) is around 19%. Harm reduction for PWID...
AIMS:Two behavioral HIV prevention interventions for people who inject drugs (PWID) infected with HI...
Two behavioral HIV prevention interventions for people who inject drugs (PWID) infected with HIV inc...
BACKGROUND:The risks of HIV transmission associated with the opioid epidemic make cost-effective pro...
Background Harm reduction strategies commonly include needle and syringe programmes (NSP), opioid su...
BACKGROUND: Pre-exposure prophylaxis with oral antiretroviral treatment (oral PrEP) for HIV-uninfect...
Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HI...
Pre-exposure prophylaxis with oral antiretroviral treatment (oral PrEP) for HIV-uninfected injection...
OBJECTIVES: The objectives of this study were to estimate the cost-effectiveness of a harm reduction...
BackgroundPersons who inject drugs (PWID) are at a disproportionately high risk of HIV infection. We...
HIV can spread rapidly between people who inject drugs (through injections and sexual transmission),...
Aims: To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting...
To end the AIDS epidemic by 2030, the global response to HIV must leave no one behind, including peo...
Abstract: Policy discussions about the feasibility of massively scaling up antiretroviral therapy (A...